Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients.
暂无分享,去创建一个
D. Katsaros | A. Bottini | L. Dogliotti | O. Bertetto | M. Donadio | S. Danese | A. Berruti | S. Bonardi | A. Farris | R. Bitossi | F. Castiglione | M. Sarobba | E. Bertone | S. Lattuada | S. Mancarella | C. Nigro | T. Volpe
[1] D. Dodwell,et al. Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study , 2004, British Journal of Cancer.
[2] J. Witjes,et al. A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life , 2003, World Journal of Urology.
[3] G. Hortobagyi,et al. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Krzakowski,et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] O. Garrone,et al. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma , 2003, Cancer.
[6] M. Piccart,et al. Chemotherapy for metastatic breast cancer-report of a European expert panel. , 2002, The Lancet. Oncology.
[7] M. Valerio,et al. First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Ellis,et al. A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] C. la Vecchia,et al. Cancer Mortality in Italy, 1997: Quantifying the Fall in Rates in Women and Men , 2001, Tumori.
[10] F. Recchia,et al. Combined 5‐Fluorouracil Infusion With Fractionated Epirubicin and Cyclophosphamide in Advanced Breast Cancer , 2001, American journal of clinical oncology.
[11] J. Jassem,et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Asselain,et al. Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first‐line doxorubicin‐containing chemotherapy , 2001, Cancer.
[13] V. Lorusso,et al. Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Osoba,et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[16] G. Bastert,et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis , 2000, Breast Cancer Research and Treatment.
[17] M. Milella,et al. Weekly epirubicin plus lonidamine in advanced breast carcinoma , 1999, Breast Cancer Research and Treatment.
[18] S. Barni,et al. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] V Torri,et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] B. Asselain,et al. Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90). , 1998, British Journal of Cancer.
[21] P. Ellis,et al. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] H. Gabra,et al. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. , 1996, British Journal of Cancer.
[23] P. Zola,et al. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Lacombe,et al. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Talbot,et al. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Demicheli,et al. Drugs ten years later: epirubicin. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[28] V. Meininger,et al. Biochemical effects of Navelbine on tubulin and associated proteins. , 1989, Seminars in oncology.
[29] Terry L. Smith,et al. Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy , 1999, Cancer.
[30] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.